ReportWire

Tag: output

  • Enbridge $1.4 Billion Project Aims to Boost Canadian Oil Flow to U.S. Refineries

    [ad_1]

    Pipeline operator Enbridge ENB 0.51%increase; green up pointing triangle will push ahead with a $1.4 billion expansion of its core network to boost deliveries of Canadian heavy oil and reach key refining markets in the U.S. Midwest and Gulf Coast.

    The Canadian energy company said Friday it reached a final investment decision on the first phase of a project to optimize its Mainline network, which is forecast to add egress capacity from Canada that will support increased production in the country and connect with what it described as the best refining markets in North America.

    Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

    [ad_2]

    Robb M. Stewart

    Source link

  • German Industrial Production Rebounds Weakly Amid Tentative Hopes Over Outlook

    [ad_1]

    Industrial production in Europe’s largest economy rebounded less than expected in September, amid hopes that the outlook could be changing for the sector ahead of large-scale government investment.

    Output rose 1.3% on month, Germany’s statistics agency Destatis said Thursday, offsetting some of the 3.7% decline in August. Economists polled by The Wall Street Journal expected a larger 2.5% uptick.

    Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

    [ad_2]

    Ed Frankl

    Source link

  • Eurozone Industrial Production Unexpectedly Expands Amid Signs Recovery for Sector

    Eurozone Industrial Production Unexpectedly Expands Amid Signs Recovery for Sector

    [ad_1]

    By Ed Frankl

    Eurozone manufacturing is showing signs of life again after industrial production jumped unexpectedly in December, further signaling that the recent slump in manufacturing in the bloc may be coming to a close.

    Total production rose on 2.6% on month in December, according to figures published Wednesday by European Union statistics…

    Master your money.

    Subscribe to MarketWatch.

    Get this article and all of MarketWatch.

    Access from any device. Anywhere. Anytime.


    Subscribe Now

    [ad_2]

    Source link

  • Saudi Arabia Halts Oil Production Capacity Increase

    Saudi Arabia Halts Oil Production Capacity Increase

    [ad_1]

    By Pierre Bertrand

    Saudi Arabian Oil Co., commonly known as Saudi Aramco, said that it has been ordered by the Saudi government to keep its oil production capacity at 12 million barrels a day.

    The oil and gas company said it received the instruction while it was working to increase production to 13 million barrels per day.

    “Aramco announces that it has received a directive from the Ministry of Energy to maintain its Maximum Sustainable Capacity (MSC) at 12 million barrels per day,” it said in a statement.

    Write to Pierre Bertrand at pierre.bertrand@wsj.com

    [ad_2]

    Source link

  • U.S. construction spending rises for the ninth month in a row in September

    U.S. construction spending rises for the ninth month in a row in September

    [ad_1]

    Construction spending rose in September, as companies and the government continued to ramp up projects across the U.S.

    Spending on construction projects rose 0.4% in September to nearly $2 trillion, the Commerce Department reported Wednesday. 

    The…

    [ad_2]

    Source link

  • Why McDonald’s is bringing back its McRib for the umpteenth time

    Why McDonald’s is bringing back its McRib for the umpteenth time

    [ad_1]

    Call it the long goodbye, fast food-style.

    McDonald’s
    MCD,
    +0.27%

    is planning to bring back its beloved McRib sandwich, just one year after giving the porky treat a “farewell tour.” The menu item is set to return next month, according to the company.

    “While it won’t be available nationwide, some lucky fans may find their favorite elusive saucy sandwich at their local McDonald’s restaurants this November,” McDonald’s said in a statement to MarketWatch on Wednesday.

    Not that the news should come as a complete surprise. McDonald’s has always employed a scarcity tactic in marketing the McRib. That is, the key to the sandwich’s appeal has been that it’s never around for long, leaving fans (including Homer Simpson) to devour it while they can.

    As Restaurant Business, a trade publication, observed last year: “If consumers think there is a shortage of a product, or that it won’t be around for long, they will rush out to get it. Think of the Great Toilet Paper Shortage in 2020 and how many people rushed out to get some the moment they thought they might run out.”

    The publication quoted McDonald’s CEO Chris Kempczinski about this approach, particularly in relation to the “farewell tour”: “The McRib is the GOAT of sandwiches on our menu. And so like the GOATs Michael Jordan, Tom Brady, and others, you’re never sure if they’re fully retired or not.”

    By all accounts, the strategy has worked: A Wall Street Journal story once noted that McDonald’s sold more than 60 million of the sandwiches over a three-year period — in spite of the fact (or maybe because of the fact) it’s available in such limited fashion.

    Further proof of the McRib’s success: It has spawned some competition. In 2021, Arby’s released a Country Style Pork Rib sandwich as a limited-time fall offering — and took cheeky aim at McDonald’s in its marketing, referring to the McRib as a “rib-shaped sandwich” (there’s some truth to that — the McRib features a boneless pork patty with no actual ribs).

    Naturally, the McRib’s return has sparked plenty of reaction on social media. One commenter on X (formerly Twitter) referred to the fact the sandwich seemingly has nine lives. Another said that McDonald’s retracting of its “farewell tour” announcement has left them having “trust issues.”

    [ad_2]

    Source link

  • Intel’s Big Chip-Making Push in Germany Hits Bottleneck

    Intel’s Big Chip-Making Push in Germany Hits Bottleneck

    [ad_1]

    Intel’s Big Chip-Making Push in Germany Hits Bottleneck

    [ad_2]

    Source link

  • A stranger in your hotel room? Kitty-litter shortages? Online attacks are causing real-world effects.

    A stranger in your hotel room? Kitty-litter shortages? Online attacks are causing real-world effects.

    [ad_1]

    It was past midnight when Alessandra Millican and a friend entered the Bellagio hotel room that was costing them hundreds of dollars a night, but unexpected noises made them stop cold.

    “We started hearing grunts,” she said. “It’s somebody waking up — we were halfway through the room and we realized there’s somebody sleeping in here.”

    Millican…

    [ad_2]

    Source link

  • Ford revenue jumps 12%, but stock dips as Wall Street spooked by shifting EV production goal

    Ford revenue jumps 12%, but stock dips as Wall Street spooked by shifting EV production goal

    [ad_1]

    Ford Motor Co. late Thursday reported quarterly profit that was about three times higher than last year’s and a 12% increase in its revenue, moving it to raise its outlook for 2023, but the beat-and-raise was overshadowed by a delay in EV production goals.

    Ford stock
    F,
    +0.44%

    initially rose about 3% after the positive results, with Chief Executive Jim Farley telling investors that the company’s goal is to match an “exciting, long-term vision” of itself with “boringly predictable execution quarter after quarter, year after year.”

    Share gains started to fade, however, as investors zeroed in on the shifted production goal, and ended the extended session down 1.2%. Ford said it expects to reach a production rate of 600,000 EVs in 2024; when it reported first-quarter earnings in May it said it would reach that milestone by the end of this year.

    The company’s EV production growth has been “disappointing,” CFRA analyst Garrett Nelson said Thursday.

    Nelson said he was “cautious” on Ford in light of the stock’s run so far this year and the possibility that “higher-for-longer” interest rates would weigh on sales after a strong first half of the year. Looming labor negotiations with the United Auto Workers are another reason for caution, he said.

    Ford earned $1.9 billion, or 47 cents a share, in the second quarter, nearly three times higher than in the year-ago period and a 4% margin, the company said. Adjusted for one-time items, the automaker earned 72 cents a share.

    Revenue rose 12% to $45 billion, Ford said, and its cash and liquidity are “persistently strong.” The revenue increase included a 39% rise for Ford’s EV business.

    Analysts polled by FactSet expected Ford to report adjusted earnings of 54 cents a share on sales of $43.17 billion.

    Supply-chain “disruptions” have persisted but are now easing, and Ford has “more work to do” to streamline its systems, reduce costs and improve quality, Farley said in the call.

    EV adoption is still in the upswing, Farley said, but the number of companies entering the market is growing even at the higher end of the market. With its varied offers, though, Ford is building EV “loyalists” to its brand, Farley said.

    Ford lifted its EBIT guidance range for the full year to between $11 billion and $12 billion. It also adjusted upward its expectations for 2023 adjusted free cash flow to between $6.5 billion and $7 billion. Capital expenditures would be between $8 billion and $9 billion, the automaker said.

    The guidance presumes “headwinds” including “global economic uncertainty and inflationary pressures, higher industrywide customer incentives and continued EV pricing pressure,” Ford said, as well as increased warranty costs and costs associated with union contract negotiations.

    On the positive side, “tailwinds” accounted for in the guidance included “improved” supply chain, higher industry volumes, upside from the its all-new Ford Super Duty truck and lower commodity costs, Ford said.

    Ford earlier this month surprised Wall Street by cutting the price of its sought-after electric pickup truck, the F-150 Lightning.

    Ford earnings close the cycle for major U.S. automakers, as Tesla Inc.
    TSLA,
    -3.27%

    reported second-quarter earnings last week and General Motors Co.
    GM,
    +1.78%

    earlier this week.

    Shares of Ford have gained 19% so far this year, matching the advance for the S&P 500 index
    SPX,
    -0.64%
    .
    The stock holds an outperformance, however, in the past three months, up 19% to the S&P’s 11%.

    See also: GM, Hyundai and other car manufacturers to build 30,000 fast EV chargers in challenge to Tesla

    [ad_2]

    Source link

  • Construction spending inches up, showing signs of a recovery in housing

    Construction spending inches up, showing signs of a recovery in housing

    [ad_1]

    The construction industry posted a slight gain in May as companies and the government increased spending on projects across the U.S.

    Spending on construction projects rose 0.9% in May to $1.93 trillion, the Commerce Department reported Monday. 

    Wall Street was expecting construction spending to rise 0.5% in April.

    Construction spending reveals how much the government and private companies spend on projects, from housing to highways. The more the U.S. spends on construction, the higher the level of economic activity. 

    The government revised spending on construction in April to 0.4% from an initial read of a 1.2% increase.

    Over the past year, construction spending was up 2.4%. 

    In terms of residential real estate, private residential construction fell 11.6% in May as compared to the previous year. It was up 2.2% as compared to April.

    Single-family construction rose on a month-over-month basis in May by 1.7%, but fell sharply by 25% from last year.

    Multifamily construction fell by 0.1% in May, but increased by 20.4% from last year.

    Spending on public residential construction rose by 0.1% from last month, and 12.3% from last year. The U.S. increased spending on public residential construction by 1.1% from last month, and 8.3% over the last year.

    The increase in spending May overall was “strong,” Stephen Stanley, chief U.S. economist at Santander U.S. Capital Markets, wrote in a note.

    “In particular, new residential activity jumped by 2.2%, reversing the cumulative declines recorded over the three prior months,” he added. “This lines up with the big increase in housing starts in May and adds to the growing body of evidence that the housing sector is bottoming out.”

    Stocks
    DJIA,
    +0.11%

    SPX,
    +0.04%

    were down in early trading on Monday. The 10-year Treasury note
    TMUBMUSD10Y,
    3.844%

    was around 3.8%.

    [ad_2]

    Source link

  • Ford Venture Gets Record $9.2 Billion Government Loan for EV Batteries

    Ford Venture Gets Record $9.2 Billion Government Loan for EV Batteries

    [ad_1]

    Ford Venture Gets Record $9.2 Billion Government Loan for EV Batteries

    [ad_2]

    Source link

  • April U.S. factory orders rise for fourth gain in five months

    April U.S. factory orders rise for fourth gain in five months

    [ad_1]

    Orders for manufactured goods rose 0.4% in April, the Commerce Department said Monday. It is the fourth increase in factory-goods orders in the past five months.

    Economists surveyed by the Wall Street Journal were expecting a 0.6% rise.

    The gain was led by transportation equipment. Excluding that sector, orders were down 0.2%.

    Durable-goods orders rose 1.1% in April, unrevised from the initial estimate last week. The advance durable-goods data is always released ahead of the full report. Nondurable-goods orders fell 0.1% in April.

    Orders for nondefense capital goods, excluding aircraft, rose a revised 1.3% in April, down slightly from the prior estimate of a 1.4% increase. The gain was led by computers and machinery.

    [ad_2]

    Source link

  • Oil prices jump more than 2% after Saudi Arabia sets July production cut

    Oil prices jump more than 2% after Saudi Arabia sets July production cut

    [ad_1]

    Oil futures opened sharply higher Sunday evening, after Saudi Arabia agreed to deliver an additional 1 million–barrel daily production cut next month as the Organization of the Petroleum Exporting Countries and its allies moved to extend existing production targets.

    Price action

    • West Texas Intermediate crude for July delivery
      CL00,
      +0.98%

      CL.1,
      +0.98%

      CLN23,
      +0.98%

      remained up $1.49, or 2.1%, at $73.23 a barrel on the New York Mercantile Exchange, after trading as high as $75.06.

    • August Brent crude
      BRN00,
      +0.87%

      BRNQ23,
      +0.87%
      ,
      the global benchmark, gained $1.59, or 2.1%, to trade at $77.72 a barrel on ICE Futures Europe, after touching $78.73 after the open.

    Market drivers

    Saudi Arabia on Sunday said it would cut oil output by 1 million barrels a day in July, and that the reduction could be extended if needed. The announcement came as OPEC+ agreed to extend current production levels through the end of 2024 at a contentious meeting in Vienna.

    See: Saudis to cut oil production by 1 million barrels a day in July as OPEC+ extends output deal

    OPEC+ agreed last October to cut production by 2 million barrels a day. Some OPEC+ members in early April announced further cuts totaling 1.6 million barrels a day through year-end, including 500,000 barrels a day in reductions by Saudi Arabia.

    Saudi Energy Minister Abdulaziz bin Salman last month warned that short sellers should “watch out” and that they would be “ouching” much as they did in early April, when the surprise cuts caused a sharp, but short-lived, spike in crude prices.

    The outcome of the meeting reinforces Saudi Arabia’s “uneasiness with the level of short positions in the market rather than signaling concerns around demand outlook,” said Giacomo Romeo, energy equity analyst at Jefferies, in a Sunday evening note to clients.

    “The open-ended part of the measure was likely put in place to discourage future short positioning,” he wrote.

    [ad_2]

    Source link

  • Saudis to cut oil production by 1 million barrels a day in July as OPEC+ extends output deal

    Saudis to cut oil production by 1 million barrels a day in July as OPEC+ extends output deal

    [ad_1]

    Saudi Arabia will voluntarily cut production by 1 million barrels a day in July, alongside an agreement by the Organization of the Petroleum Exporting Countries and its allies to stick to production targets on Sunday.

    Describing the voluntary cut as a “Saudi lollipop,” the country’s energy minister, Prince Abdulaziz bin Salman, said the July reduction could be extended if needed.

    OPEC+ — the group made up of OPEC and its Russia-led allies — concluded a contentious meeting in Vienna, with members agreeing to extend previously agreed production cuts through the end of 2024. OPEC+ agreed last October to cut output by 2 million barrels a day and followed that in April with the surprise announcement of 1.6 million barrels a day in additional cuts.

    Oil prices have fallen sharply since the October reduction amid worries over the global economic outlook, with Brent crude
    BRN00,
    +0.35%
    ,
    the global benchmark, down more than 20%. The surprise April cuts initially boosted prices, but gains were soon erased.

    [ad_2]

    Source link

  • WSJ News Exclusive | Saudi Arabia, Some OPEC Members Clash Over Oil-Production Quotas

    WSJ News Exclusive | Saudi Arabia, Some OPEC Members Clash Over Oil-Production Quotas

    [ad_1]

    Saudi Arabia, Some OPEC Members Clash Over Oil-Production Quotas

    [ad_2]

    Source link

  • French Industrial Production Rose More Than Expected in April

    French Industrial Production Rose More Than Expected in April

    [ad_1]

    By Ed Frankl

    French industrial production rebounded more than expected in April, suggesting that some pressures on output could be easing as supply bottlenecks loosen, despite the squeeze on spending caused by high inflation and rising interest rates.

    Industrial output–comprising output in manufacturing, energy and construction–rose 0.8% on month in April, after falling by 1.1% in March, data from the country’s statistics office Insee showed Friday.

    The reading is a little better than the 0.4% increase expected by economists in a poll by The Wall Street Journal

    Manufacturing output–the biggest component of industrial production–rose by 0.7% on month in April, with production in the mining, energy and water industries increasing by 1.8%.

    Food production, however, fell by 0.3%, while construction rebounded, rising 0.8% after falling in March.

    Data from France’s purchasing managers survey on Thursday showed a declining manufacturing trend in May, albeit marginally less pronounced compared with April, as the sector struggles from the effects of inflation and rising interest rates in a gloomy economic climate for industrial production across much of Europe.

    Write to Ed Frankl at edward.frankl@wsj.com

    [ad_2]

    Source link

  • The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs

    The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs

    [ad_1]

    A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications and supply shortages generate a market for unauthorized, potentially risky copycat versions of these drugs. 

    Social media buzz about the drugs has promoted the mistaken perception that the medications are appropriate for a broad swath of people who may want to shed a few pounds–with disastrous consequences for some patients, doctors say. Patients who previously recovered from eating disorders, for example, are coming in for treatment because they “have had their eating disorder reactivated by use of these medications,” said Dr. Elizabeth Wassenaar, a regional medical director at the Eating Recovery Center, which specializes in treating the disorders. Some patients have wound up in the hospital, she said, and in some cases the providers who prescribed the drugs were unaware of the patients’ eating-disorder history. “It’s a real warning to people who prescribe these medications that it’s not without risk,” she said.

    Some doctors also question whether the safety of the drugs has been adequately studied in older adults, who may have an undesirable loss of lean muscle mass when taking the medications. That complicates an ongoing debate about whether Medicare should cover these drugs for weight loss.  

    And patients of all types are put at risk, experts say, by the illegal production of knock-off versions of the medications. The Food and Drug Administration and several state pharmacy boards in recent weeks have warned that some compounding pharmacies are producing unauthorized versions of the drugs–which poses particular safety concerns for injectable drugs such as Wegovy, said David Margraf, a pharmaceutical research scientist with the Resilient Drug Supply Project at the University of Minnesota’s Center for Infectious Disease Research and Policy. “It’s not just a victimless crime,” he said. “People can be severely injured.” 

    Novo Nordisk
    NVO,
    +0.33%
    ,
    the maker of Wegovy and Ozempic, itself sought to tap the brakes on the craze around these drugs in a statement posted on its website this month, saying it’s concerned about reports of the drugs being used “for purely cosmetic or aesthetic weight loss,” unauthorized versions of the drugs hitting the market, and “insufficient clinical evaluations by some telehealth providers” promoting the drugs. 

    Drugs such as Novo Nordisk’s Wegovy, Ozempic and Rybelsus and Eli Lilly’s
    LLY,
    -0.36%

    Mounjaro mimic the effects of a gut hormone known as GLP-1, which can help control blood-sugar levels and reduce appetite. (Mounjaro also affects another hormone called GIP.) Ozempic, Rybelsus and Mounjaro are FDA-approved for treatment of type 2 diabetes, while Wegovy is approved for people with obesity and certain people with excess weight combined with weight-related medical problems. 

    Billions of dollars in drug sales hinge on the breadth of the patient population prescribed these medications. Last year, more than 5 million prescriptions for Ozempic, Mounjaro, Rybelsus or Wegovy were written for weight management, up from just 230,000 in 2019, according to data and analytics firm Komodo Health. Obesity drugs could be a $54 billion market by 2030, up from $2.4 billion in 2022, Morgan Stanley said in a report last year. Reports of GLP-1 drug users seeing improvements in addictive behaviors such as smoking and drinking have lately amplified interest in the medications.  

    The drugs have become such a cultural phenomenon that Walmart during its quarterly earnings call last week blamed the medications for a shift in consumer-spending patterns that pressured its margins. In the first quarter, the company saw “a shift to health and wellness,” John Rainey, Walmart Inc.’s
    WMT,
    +0.18%

    executive vice president and chief financial officer, said on the call with analysts. “And part of that is related to these GLP-1 drugs that are to treat diabetes,” he said, adding that the shift “comes at a lower margin, and so that has some impact on our business as well.” 

    Noom, a digital health company that for years has emphasized a behavioral approach to weight management, this week announced a new program that will make Ozempic, Wegovy, Mounjaro and other medications available to eligible patients. “Prescriptions are not the goal of our program. They’re very much an adjunct,” Dr. Linda Anegawa, Noom’s chief of medicine, told MarketWatch. Medical professionals will review patients’ entire health history, order labs to assess their metabolic health, and engage in video visits with patients as they determine what treatments might be appropriate, she said. 

    Telling your brain you’re not hungry 

    The reason GLP-1 drugs help control weight is pretty straightforward, said Dr. Daniel Drucker, who helped discover GLP-1 and is senior scientist at Lunenfeld-Tanenbaum Research Institute in Toronto. When people take these drugs, he said, they simply eat less because they feel more full. “GLP-1 will tell your brain that you’re not hungry,” he said, and people taking these medications may feel less stressed about food or find themselves thinking less about food. And the effects may go beyond eating, he said, as some people also see improvements in smoking, drinking, and other addictive or compulsive behaviors. “These are really interesting areas for further investigation,” he said. Drucker has been a consultant or speaker for Novo Nordisk, Pfizer
    PFE,
    -0.61%

    and other pharmaceutical companies. 

    Novo Nordisk said in a statement to MarketWatch that it is not conducting any dedicated clinical studies to evaluate Ozempic, Rybelsus or Wegovy in patients with substance-use disorders or addiction-related illnesses, and Eli Lilly said it does not have any studies planned for investigating tirzepatide–the active ingredient in Mounjaro–for treatment of addiction. 

    Adolescents’ use of the drugs for weight loss is a particular concern for some doctors. Wegovy is approved for treatment of obesity in children 12 and older. “The adolescent mental health crisis is unprecedented,” said Wassenaar, with many teens suffering severe mood disorders, eating disorders, and suicidality, and teens struggling with depression may think, “if I lose weight, I’ll feel better and people will like me. There’s this magic drug, and all I have to do is inject it.” And if patients can start taking these drugs as early as 12 years of age, “we just don’t know what that’s going to do to them in 10 or 20 years,” she said, because there’s not enough long-term data. 

    Novo Nordisk said in a statement to MarketWatch that “teenage obesity is linked to weight-related health problems such as high blood pressure, high cholesterol and type 2 diabetes,” and that cutting calories and increasing physical activity may not be enough for some patients. “The decision to prescribe an anti-obesity medication is at the discretion of the physician and the patient/parents,” the company said. 

    Eli Lilly said that tirzepatide is not currently being studied for chronic weight management in children or adolescents. 

    Many patients may have trouble filling lower-dose Wegovy prescriptions through September, according to drugmaker Novo Nordisk.


    Novo Nordisk via AP

    Some doctors are also concerned about broad use of the drugs among older adults. Many older adults have sarcopenia, an age-related loss of muscle mass and strength that can contribute to frailty and fall risk later in life–and losing weight can mean an additional loss of muscle mass that may not be advisable for some patients, doctors and researchers say.

    While “there’s a huge push to get Medicare to cover these drugs, it’s not really certain whether they would be helpful in this population or actually more harmful,” said Judy Butler, a research fellow at PharmedOut, a research and education project at Georgetown University Medical Center. Noom is not enrolling patients over age 60 in its new program, Anegawa said, partly because “we really don’t have enough data yet with many of these drugs in the geriatric population.” 

    In the pivotal clinical trials for Wegovy, 9% of the Wegovy-treated patients were between 65 and 75 years of age, and 1% were 75 and older, Novo Nordisk said in a statement. “No overall differences in safety or effectiveness have been observed between patients 65 years of age and older and younger adult patients,” the company said. In an ongoing cardiovascular outcomes trial, about 38% of patients are 65 or older, the company said. 

    By law, Medicare generally does not cover drugs prescribed for weight loss–although some drugmakers and industry groups are pushing to change that. Some of the drugs now generating intense demand also come with a hefty sticker price: Wegovy, for example, has an estimated annual net cost of about $13,600, according to the Institute for Clinical and Economic Review. If Medicare coverage rules changed and 10% of beneficiaries with obesity used Wegovy, total annual Medicare Part D spending on the drug could be as much as $26.8 billion, according to a recent study published in the New England Journal of Medicine. That’s more than 18% of the net total Part D spending by beneficiaries and the Medicare program in 2019.

    Dangerous copycats 

    There are potential physical as well as financial costs. Side effects of the drugs can range from nausea and vomiting to gallbladder problems, inflammation of the pancreas, and thyroid cancer.

    More broadly, some doctors question the prescribing of drugs solely based on obesity, absent other risk factors. “If somebody is obese and has diabetes, high blood pressure, and high cholesterol, losing weight may improve those parameters, but obesity on its own does not need to be treated,” said Dr. Adriane Fugh-Berman, a professor at Georgetown University Medical Center and director of PharmedOut. “It’s cardiovascular fitness that is important, no matter what weight you are,” she said. “We should stop focusing on the weight itself as a risk factor.” 

    Dr. Robert Gabbay, chief science and medical officer at the American Diabetes Association, counters that “obesity is a disease, and therefore needs to be treated as such.” Although there are people with obesity who don’t have other serious conditions, he said, “that’s relatively uncommon.” 

    Despite the concerns, shortages of the drugs persist. Novo Nordisk says it anticipates that many patients will have trouble filling lower-dose Wegovy prescriptions through September. 

    For patients who are relying on GLP-1 drugs for treatment of diabetes, even a short-term interruption in access to the drugs can cause blood-glucose levels to rise and result in serious complications, Gabbay said. Patients also tend to gradually ramp up dosage of these drugs to get to the effective dose, he said, and if they lose access to the medication “they might have to start back at the beginning again,” putting them several months behind on their treatment. 

    The shortages can also create risks for a broader set of patients, experts say, as they spur demand for copycat versions of the drugs. The approved active ingredient in Wegovy and Ozempic is semaglutide in its base form, but some compounding pharmacies may be using salt forms of semaglutide, the FDA said in a late April letter to the National Association of Boards of Pharmacy. “We are not aware of any basis for compounding a drug using these semaglutide salts that would meet federal law requirements” restricting the types of active ingredients used in compounding, the FDA said in the letter. Boards of pharmacy in several states, including West Virginia, North Carolina and Mississippi, have also recently issued warnings about compounded semaglutide. 

    Novo Nordisk said in the statement posted on its website this month that it is “actively monitoring and taking action against” entities unlawfully selling compounded semaglutide, adding that no FDA-approved generic versions of semaglutide currently exist. 

    Unauthorized compounded versions of the drugs could raise serious concerns about sterility and other quality-control issues, the Resilient Drug Supply Project’s Margraf said. “If this drug is in high demand and there isn’t enough supply, people will find a way to get it from a gray-market source,” he said. “People are going to find ways around the laws and potentially harm patients.” 

    [ad_2]

    Source link

  • Boeing Faces New 737 MAX Test After Deliveries Halted. The Stock Is Falling.

    Boeing Faces New 737 MAX Test After Deliveries Halted. The Stock Is Falling.

    [ad_1]

    It isn’t what investors want to hear.



    Boeing


    (ticker: BA) has run into a new problem with its 737 MAX jet. The issue will test investors nerves in coming weeks, and raise more questions about the company’s ability to increase production in 2023.

    [ad_2]

    Source link

  • Soaring oil prices: 6 things investors need to know about the surprise OPEC+ production cuts

    Soaring oil prices: 6 things investors need to know about the surprise OPEC+ production cuts

    [ad_1]

    The Organization of the Petroleum Exporting Countries and its allies said they decided Sunday to cut production in an effort to support oil-market stability, but that offers little comfort to consumers worried about inflation and an expected spike in fuel demand during the coming summer driving season.

    The surprise output reduction by the group known as OPEC+ starting in May also comes at a particularly vulnerable time for the U.S., which may not be able to quickly increase its own production.

    “The nature and timing of the decision are shocking, since prices have been only moderate pressured from the banking mini-crisis and the market is expected to tighten later this year,” said Michael Lynch, president of Strategic Energy & Economic Research.

    “OPEC+, and especially the Saudis, seem to be signaling a strong desire to punish short sellers and pre-empt possible demand weakness,” he told MarketWatch. Also, “the impact on inflation…could mean an anemic summer driving season.”

    What happened?

    OPEC and its allies, a group known as OPEC+, announced voluntary production “adjustments” on Sunday that will take effect starting in May and run through to the end of the year.

    The move was unusual, as there was no indication that any change to production would be made and OPEC+ ministers weren’t scheduled to officially hold an output decision-making meeting until June 4.

    The OPEC+ Joint Ministerial Monitoring Committee, however, did hold a meeting on Monday, as it does every two months. The committee has no ability to make decisions on production, but has the authority to request an OPEC and non-OPEC ministerial meeting at any time to address market developments.

    The JMMC had been expected to discuss a number of oil-market issues, and confirm that previously announced cuts of 2 million barrels a day would remain in effect. The committee on Monday indeed reaffirmed its commitment to that previous agreement, but also pointed out Sunday’s announcement.

    “Unlike cuts in the past that were more ‘paper cuts’ to quotas with many countries already producing below quota, these are real voluntary cuts from countries producing at or above quotas,” said Rebecca Babin, senior energy trader at CIBC Private Wealth U.S., in emailed commentary. That means this will be “far more impactful than the 2 million barrels cut” announced in October 2022.

    Saudi Arabia will take on the biggest reduction, cutting oil output by 500,000 barrels a day. Other barrel-per-day cuts include Iraq with 211,000, United Arab Emirates 144,000, Kuwait 128,000, Kazakhstan 78,000, Algeria 48,000, Oman 40,000 and Gabon 8,000. Those total 1.157 million barrels a day.

    The cuts, however, are in addition to the previous OPEC+ production cuts of 2 million barrels a day, as well as the extension of Russia’s reduction of 500,000 barrels a day in retaliation to western oil-price caps and sanctions. That brings the total output reductions to 3.657 million barrels a day.

    What prompted the cut?

    Saudi Arabia’s Ministry of Energy on Sunday, as well as the JMMC in a statement Monday, said that the cuts are a “precautionary measure aimed at supporting the stability of the oil market.”

    Some news reports and analysts have speculated that Saudi Arabia, a member of OPEC and among the world’s top oil producers, and other major oil producers made the surprise move to cut output because of recent comments made by U.S. Energy Secretary Jennifer Granholm.

    Read: Trigger for Saudi oil production move was comment that U.S. would not refill SPR this year, report says

    On March 23, Granholm said that it may take years for the U.S. to refill its Strategic Petroleum Reserve. She appeared to walk back those comments on March 28, with Reuters reporting that she said the U.S. could start buying back crude oil for the SPR late this year.

    The Biden administration last year announced the emergency sale of 180 million barrels of SPR crude to help lower gasoline prices, and has said it would refill the reserve when oil prices fell to around $70 a barrel.

    U.S. benchmark West Texas Intermediate crude oil fell below $70 a barrel to their lowest level in 15 months on March 21.

    Why was the market so surprised?

    The OPEC+ decision took the financial market by surprise.

    “If fully delivered, the announced cut would further tighten an already fundamentally tight oil market, driving the Brent benchmark towards $100 per barrel sooner than previously expected, and would push the price to around $110 per barrel this summer,” said Jorge Leon, senior vice president at Rystad Energy.

    Before the new OPEC+ cuts, Rystad Energy was anticipating the crude-oil market to be in a supply deficit to the “tune of 1.4 million” barrels a day between May and August, he said in emailed commentary. The voluntary cuts will put “upside pressure on prices from a fundamentals perspective, offering support of around $10 per barrel.”

    On Monday, the front-month May WTI oil futures contract
    CLK23,
    -0.01%

    CL.1,
    -0.01%

    climbed 6.4% to trade above $80.50 a barrel ahead of the closing bell on the New York Mercantile Exchange. Global benchmark June Brent oil
    BRNM23,
    -0.18%

    BRN00,
    -0.18%

    rose $4.75, or 6.3%, to close at $80.42 a barrel on ICE Futures Europe.

    “Positioning in crude is extremely light after the recent financial market driven weakness,” said Babin. Last week’s rally was driven primarily by short covering and modest re-engagement from long buyers,” she said, adding that the long position, or bets that oil will rise in value, is “very modest, with the managed money long-short ratio at 2.5, the lowest since December 2022.”

    Large short positions held by speculative traders can make for more explosive rallies as “weak-handed” players are forced to buy futures to close out losing trades.

    Craig Golinowski, managing partner at Carbon Infrastructure Partners, also pointed out to MarketWatch that paper market for oil is “very thin.” Fewer participants and financial flows have created downside pressure on oil, he said, so OPEC is “physically managing production to maintain a tight market to ensure investment into production remains stable, regardless of the paper market for oil.”

    The energy market saw broad gains, with company shares and exchange-traded funds, including the Energy Select Sector SPDR Fund
    XLE,
    +4.53%
    ,
    rallying in the wake of the OPEC+ news.

    St. Louis Federal Reserve President James Bullard on Monday said the spike in oil prices after the OPEC+ cut announcement may make the central bank’s inflation-fighting job “a little more difficult,” though it is too soon to know for sure.

    The latest spike in oil prices may “play a hand in what the Fed does next regarding its fight against inflation,” particularly if the latest jump in oil is sustained as oil at the current level “won’t be doing the inflation rate any favors,” said Tim Waterer, chief market analyst at Kohle Capital Markets.

    Read: Oil-production cuts could force Fed to raise interest rates even higher to fight inflation

    Will OPEC+ lose market share?

    In the past, OPEC+ has been concerned about the loss of oil-market share when it decides to make production cuts.

    This time, however, there is “limited threat to market share,” said CIBC Private Wealth’s Babin.

    Previously, when OPEC+ cut production, they would lose market share to U.S. shale oil producers, she said. “However, “U.S. shale producers have entered a period where growth is limited due to financial discipline.”

    Recent developments in regional banks has “likely lowered shale producers’ ability to quickly get capital to increase production,” said Babin.

    Total U.S. petroleum production stood at 12.2 million barrels a day as of the week ended March 24, down 100,000 barrels per day from a week earlier, according to data from the Energy Information Administration.

    OPEC would usually “hesitate to reduce barrels, with fears of ceding market share to U.S. shale, but the slowing of U.S. production and their dedication to a disciplined approach has alleviated the Saudi’s fear of rapid U.S. growth,” said Alex Hodes, energy analyst at StoneX.

    What are the geopolitical implications?

    Meanwhile, James Swanston, Middle East and North Africa economist at Capital Economics, in a note said the OPEC+ move was likely motivated by geopolitics and Saudi Arabia’s “shift away from the West.”

    Saudi Arabia’s ties with the U.S. are “fraying,” he said.

    Swanston also said the production decision has implications for the future of OPEC+ oil policy, as well as the “patience of members, particularly, the UAE.”

    The U.A.E. agreed to these voluntary output cuts, but it was reported last month that officials were growing impatient at the bearish OPEC+ stance and had discussed internally whether to leave the group, said Swanston.

    The Wall Street Journal: Saudi Arabia and U.A.E. Clash Over Oil, Yemen as Rift Grows

    The U.A.E. wants to “increase oil output sooner rather than later as shown by its move to bring forward its oil production capacity target from 3.1 [million barrels per day] currently to 5 million bpd by 2027,” instead of the year 2030, said Swanston.

    He said the U.A.E. had twice previously threatened to leave OPEC+ and that there was speculation that the U.A.E. was strongly against the Saudi-led decision to cut OPEC+ oil output quotas by 2 million bpd in October.

    “If the OPEC+ strategy of lower oil production persists, then tensions could escalate, and the U.A.E. could ultimately opt to leave OPEC+,” Swanston said.

    What do the cuts say about demand?

    The production cuts will take effect in May, which is “right ahead of Memorial Day and the start of U.S. driving season,” said Stacey Morris, head of energy research with VettaFi.

    Given that, “it could be another summer with painful prices at the [gasoline] pump,” she said.

    The average price for regular unleaded gasoline stood at $3.506 a gallon on Monday, up from $3.439 a week ago, but down from $4.192 a year ago, according to AAA.

    Read: The surprise OPEC+ oil production cuts will increase gas prices — here’s how much

    Still, some traders may interpret the OPEC+ cut as a sign of weaker than expected demand for physical markets, given that OPEC+ possesses “some of the best information available in regards to the global physical oil markets,” said Rob Thummel, portfolio manager at Tortoise.

    However, “ we still expect global oil demand to accelerate throughout 2023, reaching a record high in the second half the year,” he said.

    Global oil inventories are below normal and will likely “remain below normal as higher demand and less supply deplete inventories throughout the year,” Thummel said, noting that Tortoise expects oil prices to be range bound between $85 and $95 for the year.

    [ad_2]

    Source link